TABLE 4.
Pharmacokinetic parameters of DAAs, ritonavir, and ribavirin in HCV/HIV-coinfected subjects at week 4
| Antiviral and parameter | Geometric mean (% coefficient of variation) |
|
|---|---|---|
| Darunavir 800 mg QD (n = 10) | Darunavir 600 mg BID (n = 12) | |
| Ombitasvir | ||
| Cmax (ng/ml) | 92.6 (35) | 71.7 (38) |
| AUC24 (ng · h/ml) | 1,120 (36) | 944 (40) |
| C24 (ng/ml) | 20 (70) | 21 (45) |
| Paritaprevir | ||
| Cmax (ng/ml) | 1,440 (106) | 1,240 (109) |
| AUC24 (ng · h/ml) | 7,650 (139) | 6,710 (124) |
| C24 (ng/ml) | 19 (218) | 44 (133) |
| Ritonavir | ||
| Cmax (ng/ml) | 881 (46) | 1,209 (64) |
| AUCt (ng · h/ml) | 6,910 (32) | 7,517 (67)a |
| C24 (ng/ml) | 48 (76) | NAb |
| Dasabuvir | ||
| Cmax (ng/ml) | 725 (45) | 572 (39) |
| AUC12 (ng · h/ml) | 4,400 (48) | 3,510 (40) |
| C12 (ng/ml) | 198 (33) | 118 (46) |
| Ribavirin | ||
| Cmax (ng/ml) | 2,210 (24) | 2,810 (31) |
| AUC12 (ng · h/ml) | 21,500 (27) | 27,400 (36) |
| C12 (ng/ml) | 1,610 (34) | 1,970 (44) |
a
Value is AUC12.
b
NA, not applicable since RTV was dosed BID.